

August 23, 2016 • For Immediate Release
Contact: Greg Leaf • (651) 271.2511 • greg@groupleaf.com

Vestaron Announces Manufacturing Partnership With Capua Bioservices

August 23, 2016 – (Kalamazoo, Michigan) – Vestaron Corporation, a developer of novel, naturally occurring peptides with anti-insect properties, today announced the signing of a multi-year manufacturing agreement with Capua Bioservices for production of its Spear™ family of products. “We are very excited about engaging with Capua for microbial fermentation, focusing on scale-up and commercial manufacturing.” commented John Sorenson, Vestaron’s President and CEO. “Capua Bioservices is a world class organization with extensive experience in the fermentation of the particular type of yeast that we’re using, and we consider this a critical link in our commercialization of Spear™ products.”

Spear™ products are developed from naturally occurring peptides with anti-insect properties. These bioinsecticides are non-toxic to humans, mammals, birds, fish, honeybees, and several other beneficial insects, and the absence of toxic residues give growers maximum flexibility in growing and harvesting their crops. Spear™ products have the same effectiveness in controlling insects as harsher synthetic insecticides, but offer the safety of biologicals- a great combination for both growers and consumers!

Capua BioServices is a global provider of high-quality services in the field of custom microbial process development and manufacturing. They offer dedicated fermentation based solutions for applications in pharma, food, feed and other bio-industrial markets. They are one of the largest, independent microbial contract manufacturing facilities located in Western-Europe, with a total fermentation capacity of about 1400 m³. The Company is headquartered in Capua (Italy). Over the past 50 years, they have built a track record based on their extensive experience in working with a variety of bacterial, yeast and fungal systems.

About Vestaron Corporation

Vestaron Corporation exploits the natural insecticidal properties of a class of peptides which have potent insect killing potential, but which are safe to humans, birds, fish, and the environment. These peptides utilize new modes of action that have never before been used for insect control, and therefore do not suffer from insect resistance. In addition to the bioinsecticides, the Company is also leveraging its peptide technology with the development of traits and synthetics that also have a favorable safety spectrum.

More information at www.vestaron.com

Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company’s actual results may differ materially from the Company’s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company’s ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, ability to hire required personnel, the risk of whether products result from development activities, protection of the Company’s intellectual property portfolio, the risk associated with obtaining the necessary regulatory approvals, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other potential factors. As a result, you are cautioned not to put any undue reliance on any forward-looking statement. Except as required by law, the Company assumes no obligation to update the forward-looking statements, which are made as of the date hereof, even if new information becomes available in the future.

.....